CYP2C19 polymorphisms in patients with gastric and colorectal carcinoma

被引：8

作者：

Tamer L. ^{[1
,6
]}

Ercan B. ^{[1
]}

Ercan S. ^{[2
]}

Ateş N. ^{[3
]}

Ateş C. ^{[5
]}

Öcal K. ^{[4
]}

Dirlik M. ^{[4
]}

Aydin S. ^{[4
]}

Atik U. ^{[1
]}

机构：

[1] Department of Biochemistry, Mersin University

[2] Department of Bioistatistics, Mersin University

[3] Department of Medical Biology and Genetics, Mersin University

[4] Department of General Surgery, Mersin University

[5] Department of General Surgery, Kocaeli University

[6] Mersin University, Medical Faculty, Department of Biochemistry, 33079, Mersin

来源：

International Journal of Gastrointestinal Cancer | 2006年 / 37卷 / 1期

关键词：

CYP2C19; Gastric and colorectal carcinomas; Polymorphism;

D O I：

10.1385/IJGC:37:1:1

中图分类号：

学科分类号：

摘要：

Background: It has been reported that up to 80% of human cancers arise as a consequence of environmental exposure and host susceptibility factors. Environmental carcinogens are predominantly metabolized by the cytochrome P450 (CYP) superfamily of drug- or xenobiotic-metabolizing enzymes. Genetic variations in these enzymes affect individuals' susceptibility to carcinogens. Aim of the study: The aim of this study was to evaluate the relationship between CYP2C19 polymorphism and susceptibility to these cancers by means of CYP2C19 genotyping among Turkish subjects. Methods: DNAof subjects were isolated from leukocytes by high pure template preparation kit (Roche Diagnostics, GmbH, Mannheim, Germany) and genotypes were detected by LightCycler CYP2C19 Mutation Detection Kit by real-time PCR with LightCycler instrument (Roche Diagnostics, cat. no. 3113914). Results: Being male was associated with a 3.5-fold (OR: 4.27, CI: 2.27-8.05) and 4.27-fold (OR: 3.50, CI: 1.948-6.301) risk for colorectal and gastric carcinoma, respectively. The CYP2C19*3 heterozygote genotype was not found in either gastric or colorectal carcinoma patients. Although the frequency of CYP2C19*2 heterozygote genotype is high in patients with gastric and colorectal carcinoma, it is not significantly associated with cancer (OR: 1.79, CI: 0.829-3.865 and OR: 1.998, CI: 0.961-4.154, respectively). Conclusion: Although the frequency of CYP2C19*2 heterozygote genotype is high in our patients with gastric and colorectal carcinoma, there is no the relationship between CYP2C19 polymorphism and susceptibility to these cancer. © Copyright 2006 by Humana Press Inc. All rights of any nature whatsoever reserved.

引用

页码：1 / 5

页数：4

共 17 条

[1] Saadat I., Saadat M., Glutathione S-transferase M1 and T1 null genotypes and the risk of gastric and colorectal cancers, Cancer Lett, 169, pp. 21-26, (2001)
[2] Modugno F., Knoll C., Kanbour-Shakir A., Romkes M., A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis, Breast Cancer Res Treat, 82, pp. 191-197, (2003)
[3] Miller J.A., Miller E.C., Some historical aspects of N-aryl carcinogens and their metabolic activation, Environ Health Perspect, 49, pp. 3-12, (1983)
[4] Nelson D.R., Koymans L., Kamataki T., Et al., P450 superfamily: Update on new sequences, gene mapping, accession numbers and nomenclature, Pharmacogenetics, 6, pp. 1-42, (1996)
[5] Xie H.G., Kim R.B., Wood A.J., Stein C.M., Molecular basis of ethnic differences in drug disposition and response, Annu Rev Pharmacol Toxicol, 41, pp. 815-850, (2001)
[6] Shi W.X., Chen S.Q., Frequencies of poor metabolizers of cytochrome P450 2C19 in esophagus cancer, stomach cancer, lung cancer and bladder cancer in Chinese population, World J Gastroenterol, 10, pp. 1961-1963, (2004)
[7] Agundez J.A., Cytochrome P450 gene polymorphism and cancer, Curr Drug Metab, 5, pp. 211-224, (2004)
[8] Brockton N., Little J., Sharp L., Cotton S.C., N-Acetyltransferase and colorectal cancer: A huge review, Am J Epidomiol, 151, pp. 846-881, (2000)
[9] Rooney P.H., Murray G.I., Stevenson D.A., Haites N.E., Cassidy J., McLeod H.L., Comparative genomic hybridization and chromosomal instability in solid tumours, Br J Cancer, 80, pp. 862-873, (1999)
[10] Howson C.P., Hiyama T., Wynder E.L., The decline in gastric cancer: Epidemiology of an unplanned triumph, Epidemiol Rev, 8, pp. 1-27, (1986)

← 1 2 →